Study of final height in Turner's syndrome: ethnic and genetic influences

Rochiccioli, P; Dávid, M; Malpuech, Guillaume; Colle, M.; Limal, Jean-Marie; Battin, J; Mariani, Raffaella; Sultan, C.; Nivelon, J L; Simonin, G.; Bost, M; Chatelain, Pierre; Bertrand, Anne-Marie; Freycon, R; Bouquier, Julie; Pierron, P

doi:10.1111/j.1651-2227.1994.tb18099.x

Cited by 72 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As emphasized earlier by Zachmann et al [4], this figure is less significant than that obtained in the normal population where the correlation coefficient is 0.71 [17]. In other pathological conditions with short stature such as hypopituitarism [22, 23]or Turner syndrome [24, 25], correlation coefficients varying between 0.6 and 0.8 have been reported. Thus, target height is the most significant predictor of adult height in hypopituitary and Turner patients as in normal subjects.…”

Section: Discussionmentioning

confidence: 63%

Pubertal Growth as a Determinant of Adult Height in Boys with Constitutional Delay of Growth and Puberty

Rensonnet¹,

Kanen²,

Coremans³

et al. 1999

Horm Res Paediatr

View full text Add to dashboard Cite

In boys with constitutional delay of growth and puberty, adult height may be inconsistent with parental (target) height. We aimed at studying which period of growth was important to account for adult height being above or below target height. In this retrospective study, adult height measured after 20 years in 39 patients was compared with target height and height data obtained at about 6 and 12 years of age and at diagnosis of delayed puberty (mean 14.6 years). Twenty-eight patients were untreated while 11 received testosterone enanthate (50 or 100 mg/month for 6 months). The growth data from both groups were pooled since they were not different. On average, the adult height standard deviation score (–0.6 ± 0.8, mean ± SD) was similar to target height (–0.5 ± 0.6). There were, however, marked individual differences since adult height varied between 1.7 SD (11 cm) below target height and 1.4 SD (9.5 cm) above target height. Multiple regression analysis showed that the most significant determinant of the difference between adult height and target height was height catch up during puberty (p < 0.002). We conclude that the magnitude of height catch up during puberty is a significant determinant of adult height in boys with constitutional delay of growth and puberty. Thus, optimizing pubertal growth may be a relevant therapeutic aim for adult height in boys with short stature and delayed puberty.

show abstract

Section: Discussionmentioning

confidence: 63%

Pubertal Growth as a Determinant of Adult Height in Boys with Constitutional Delay of Growth and Puberty

Rensonnet¹,

Kanen²,

Coremans³

et al. 1999

Horm Res Paediatr

View full text Add to dashboard Cite

show abstract

“…However, hypergonadotropic hypogonadism occurs in virtually all affected individuals and short stature is a major confronting issue among patients. The mean adult height in untreated patients is approximately 20 cm shorter than that of the general female population2,3).…”

Section: Introductionmentioning

confidence: 86%

Response to three years of growth hormone therapy in girls with Turner syndrome

Park

Lee

et al. 2013

Ann Pediatr Endocrinol Metab

View full text Add to dashboard Cite

PurposeShort stature is the most common finding in patients with Turner syndrome. Improving the final adult height in these patients is a challenge both for the patients and physicians. We investigated the clinical response of patients to growth hormone treatment for height improvement over the period of three years.MethodsReview of medical records from 27 patients with Turner syndrome treated with recombinant human growth hormone for more than 3 years was done. Differences in the changes of height standard deviation scores according to karyotype were measured and factors influencing the height changes were analyzed.ResultsThe response to recombinant human growth hormone was an increase in the height of the subjects to a mean value of 1.1 standard deviation for subjects with Turner syndrome at the end of the 3-year treatment. The height increment in the first year was highest. The height standard deviation score in the third year was negatively correlated with the age at the beginning of the recombinant human growth hormone treatment. Different karyotypes in subjects did not seem to affect the height changes.ConclusionEarly growth hormone administration in subjects with Turner syndrome is helpful to improve height response to the treatment.

show abstract

“…Short stature is the single most common physical abnormality in TS, with untreated individuals achieving an average adult stature 20 cm (8 in) shorter than that of their peers [4, 5, 6, 7, 8, 9]. It is widely accepted that growth in girls with TS has four cardinal features: (1) moderate intrauterine growth retardation, (2) normal growth velocity between birth and 3 years of age, (3) decreasing height velocity between ages 3 and 12 years, and (4) failure to experience a pubertal growth spurt [2, 6, 10, 11, 12].…”

Section: Introductionmentioning

confidence: 99%

Growth Failure in Early Life: An Important Manifestation of Turner Syndrome

et al. 2002

View full text Add to dashboard Cite

The goals of this study were to test the hypothesis that girls with Turner syndrome (TS) experience growth failure early in life and to establish model-based normative growth charts for 0- to 8-year-old American girls with TS. Full-term girls with TS who had 5 or more measurements of height obtained during their first 10 years of life prior to initiation of growth hormone, estrogen and/or androgen therapy were eligible for this study. A nonlinear mixed-effects model comprising the first two components of the infancy-childhood-puberty (ICP) model of growth was fitted to the longitudinal height measurements and compared with those of healthy American girls. Height measurements (n = 1,146) from 112 girls with TS (45,X: 57.1%; 45,X/46,XX: 12.5%; 46,X, iso(X): 4.5%, and other: 25.9%) were analyzed. Mean height SDS fell from –0.68 at birth to –1.60 at 1 year, –1.80 at 2 years and –1.95 at 3 years. When compared to controls (676 girls, 4,537 measurements), girls with TS grew more slowly due to three principal factors: a slow growth rate of the infancy component, a slow growth rate at the onset of the childhood component, and delayed onset of the childhood component. Traditional concepts of growth failure in TS should be revised. Physicians should consider the diagnosis of TS in any girl with unexplained failure to thrive or short stature, even in the first 3 years of life.

show abstract

Study of final height in Turner's syndrome: ethnic and genetic influences

Cited by 72 publications

References 13 publications

Pubertal Growth as a Determinant of Adult Height in Boys with Constitutional Delay of Growth and Puberty

Pubertal Growth as a Determinant of Adult Height in Boys with Constitutional Delay of Growth and Puberty

Response to three years of growth hormone therapy in girls with Turner syndrome

Growth Failure in Early Life: An Important Manifestation of Turner Syndrome

Contact Info

Product

Resources

About